Fortress Biotech Inc (FBIO) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular m...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

KeepYourDayJob Aug. 18 at 11:10 PM

$FBIO That did not age well🤡

0 · Reply

braves1983 Aug. 18 at 3:17 PM

$FBIO welp another red day here

0 · Reply

ShibWillow Aug. 17 at 8:53 PM

Looks like Volume is shifting to MLEC now 🚀 MLEC has 573k shares remaining to public Look at what WETO / IPST did on similar share numbers today. MLEC getting squeezed now - Added a big position for a parabolic run! $FBIO $SNDX $NBIS $TGTX trending

0 · Reply

drose0527 Aug. 17 at 5:20 PM

$FBIO climbing the hill little by little! Just like a good little stock

0 · Reply

braves1983 Aug. 17 at 5:02 PM

$FBIO never ever 2 days in a row here. Never. Barely green Friday and right back to a blood bath Monday. Yay. So lucky

1 · Reply

drose0527 Aug. 15 at 12:32 PM

$AUR setting up for a nice 50% gain here in AUR $IOVA $AQST $BCRX $FBIO

4 · Reply

Henry20feb_ Aug. 15 at 5:53 AM

$FBIO They are getting there: Revenue ↑ + Commercial traction ↑ + Expenses ↓ sharply + Debt ↓ + Cash ↑ enormously + External financing of partnered assets + First royalty streams appearing.

1 · Reply

FinSUN Aug. 14 at 10:44 PM

$FBIOP $FBIO debt holders first, then insiders... and insiders want OUT... the whole Fortress capital and business shenanigan is all about sell to a third party... damn, it's the entire principle business model... When they sell.. and they will sell, they will convert, get the majority of the company, vote YES to an acquisition that is convenient to them and retire... by the time that happens they will the interest due to preferred will obliterate any current commons' OS number... Maybe selling to someone that will repeat the game... rinse and repeat. All you can do is trade. The ultimate game of this play is NOT shareholderd value, not the way you would expect from a public company. If you don't get this you will waste years and grow bitter. Understanding the capital structure, the governance and the incentives is 90% of the game in stocks like this.. the other 10% is knowing how to trade a manipulated and structurally drugged small cap, like many others.

1 · Reply

KeepYourDayJob Aug. 14 at 9:40 PM

$FBIO heck of a comeback!

0 · Reply

makrodimutross Aug. 14 at 5:35 PM

$FBIO $FBIOP One of these EITHER OR conditions were met at the time of the PRV Sale. (Positive net assets) The other condition (Net profits) is on track to be met by next year. "Fiduciary duty to common shareholders" is a joke. Was it "fiduciary duty" to pay down the Oaktree Loan? Resoundingly, YES. Likewise, it would also be considered "fiduciary duty" to pay the arrears owed to preferred stockholders. They simply don't care, and refuse to communicate with earnings calls, or even reply to emails from concerned investors. The only acceptable answer to this would be if they are negotiating with potential partners, and in possession of significant definitive material non-public information.

1 · Reply

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

FBIOP

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Fortress Biotech Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Fortress Biotech Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Fortress Biotech Quarterly report: Q2 2026

Aug 12, 2026, 4:01 PM EDT - 6 days ago

Market Cap	93.68M
Revenue (ttm)	63.26M
Net Income (ttm)	6.82M
EPS (ttm)	N/A
PE Ratio	1.11
Forward PE	N/A
Profit Margin	10.78%
Debt to Equity Ratio	0.17

Volume	593,100
Avg Vol	653,874
Day's Range	N/A - N/A
Shares Out	33.22M
Stochastic %K	70%
Beta	1.21
Analysts	Strong Sell
Price Target	$11.00